Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib Combined With PD-1 Inhibitor in First-line Intrahepatic Cholangiocarcinoma
NCT05913661Phase 2Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2023
- Primary completion
- Nov 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pemigatinib, sintilimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Sun Yat-sen Memorial Hospital. Status: unknown.
02
Drugs
pemigatinibsintilimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05913661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05913661.